Meret Facklam-Martin
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposure.
Journal: Frontiers in immunology
Published: March 24, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.
Journal: Nature communications
Published: January 30, 2023
Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside.
Journal: Journal of pharmaceutical sciences
Published: January 26, 2021
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
Journal: JAMA neurology
Published: June 19, 2018
Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities.
Journal: Current pharmacology reports
Published: March 07, 2017
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: May 23, 2016
Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: May 17, 2016
Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
Journal: Clinical pharmacology in drug development
Published: April 08, 2016
Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: March 15, 2016
Combining 'Bottom-Up' and 'Top-Down' Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example.
Journal: Clinical pharmacokinetics
Published: December 31, 2015
Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers.
Journal: Psychopharmacology
Published: September 22, 2015
Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
Journal: Clinical pharmacokinetics
Published: September 06, 2015
Last Updated: 09/26/2026